Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non–Small-Cell Lung Cancer

Früh, Martin; Rolland, Estelle; Pignon, Jean-Pierre; Seymour, Lesley; Ding, Keyue; Tribodet, Hélène; Winton, Timothy; Chevalier, Thierry Le; Scagliotti, Giorgio Vittorio; Douillard, Jean Yves; Spiro, Stephen; Shepherd, Frances A.

doi:10.1200/jco.2008.16.2727

Cited by 175 publications

(103 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fruh et al analyzed the effects of age on cisplatin-based adjuvant chemotherapy using patient-level data from the Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis. 26 In this analysis, they found that older patients (70 years) received lower total cisplatin doses compared with younger patients (<65 years) and those considered to be in the middle age category (65-69 years). They found that there were no significant differences in either OS or event-free survival among the 3 age groups studied.…”

Section: Discussionmentioning

confidence: 79%

Effect of age on the efficacy of adjuvant chemotherapy for resected non–small cell lung cancer

Ganti¹,

Williams

Gajra

et al. 2015

Cancer

View full text Add to dashboard Cite

BACKGROUND: Adjuvant chemotherapy after surgical resection improves outcomes for patients with early-stage non-small cell lung cancer (NSCLC). To the authors' knowledge, there are no published prospective trials to date of adjuvant chemotherapy after surgical resection administered exclusively in older patients. In the current study, the authors sought to evaluate the efficacy of adjuvant chemotherapy in older patients in a Veterans Health Administration cohort. METHODS: Patients who underwent surgical resection for American Joint Committee on Cancer stages IB to III NSCLC between 2001 and 2011 were analyzed. Data regarding patient demographics and comorbidities, tumor characteristics, and primary treatment were collected. Patients were divided into 2 groups based on age at diagnosis: those aged <70 years and those aged 70 years. The primary exposure was use of adjuvant chemotherapy. A Cox proportional hazards model was used to estimate the significance of patient characteristics. Survival curves were estimated using the Kaplan-Meier method and group comparisons were performed using the log-rank test. RESULTS: The analysis included 7593 patients who underwent surgical resection for stage IB to stage III NSCLC. Among these, 2897 patients (38%) were aged 70 years. The percentage of older patients who received adjuvant chemotherapy was approximately one-half that of younger patients who did so (15.3% vs 31.6%; P<.0001). Carboplatin-based doublets were used most often in all patients (64.6%). Both younger patients (hazard ratio, 0.79; 95% confidence interval, 0.72-0.86) and older patients (hazard ratio, 0.81; 95% confidence interval, 0.71-0.92) were found to have a lower risk of death with receipt of adjuvant chemotherapy. CONCLUSIONS: Older patients derive a similar magnitude of benefit from adjuvant chemotherapy as younger patients and therefore adjuvant chemotherapy should not be withheld based on age alone. Cancer 2015;121:2578-85. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.

show abstract

Section: Discussionmentioning

confidence: 79%

Effect of age on the efficacy of adjuvant chemotherapy for resected non–small cell lung cancer

Ganti¹,

Williams

Gajra

et al. 2015

Cancer

View full text Add to dashboard Cite

show abstract

“…Adjuvant chemotherapies have increased survival rates by approximately 5% in 5 years in NSCLC, which does not appear to be satisfactory (3,9). Severe toxicities are occasionally observed in patients treated with CDDP-based chemotherapies, and chemotherapy-related death has been one of the major problems with adjuvant chemotherapies.…”

Section: Introductionmentioning

confidence: 99%

Feasibility of adjuvant chemotherapy with S-1 consisting of a 4-week administration and a two-week rest period in patients with completely resected non-small cell lung cancer

Okumura

Sasaki

Satoh

et al. 2012

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The efficacy of adjuvant chemotherapy with S-1 in patients with completely resected non-small cell lung cancer (NSCLC) has yet to be clarified, and the appropriate schedule for the adjuvant chemotherapy with S-1 remains unknown. A phase II study was conducted to evaluate the feasibility and efficacy of adjuvant chemotherapy with S-1. Patients enrolled in this study were 20-75 years old, had pathological stage IB-IIIA NSCLC, and had received complete resection of NSCLC. S-1 (80 mg/m 2 ) was administered orally to the patients for four weeks followed by a two-week rest period (conventional schedule), for a maximum of eight cycles. The primary endpoint was relative dose intensity (RDI), while the secondary endpoints were safety and 1 year of disease-free survival (1y-DFS). Between

show abstract

“…Previous studies have shown that many factors can affect the efficacy and outcome of post-operative chemotherapy with the NP regimen (Früh et al, 2008). We stratified the patients and found that patients with NSCLC at <55 years of age, with squamous carcinoma at stage I, survived significantly longer than those at older age, with adenocarcinoma or stage II or IIIA.…”

Section: Discussionmentioning

confidence: 91%

Post-operative Treatment with Cisplatin and Vinorelbine in Chinese Patients with Non-small Cell Lung Cancer: A Clinical Prospective Analysis of 451 Patients

Wang

Liu²,

Huang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non–Small-Cell Lung Cancer

Abstract: Adjuvant cisplatin-based chemotherapy should not be withheld from elderly patients with NSCLC purely on the basis of age.

Cited by 175 publications

References 30 publications

Effect of age on the efficacy of adjuvant chemotherapy for resected non–small cell lung cancer

Effect of age on the efficacy of adjuvant chemotherapy for resected non–small cell lung cancer

Feasibility of adjuvant chemotherapy with S-1 consisting of a 4-week administration and a two-week rest period in patients with completely resected non-small cell lung cancer

Post-operative Treatment with Cisplatin and Vinorelbine in Chinese Patients with Non-small Cell Lung Cancer: A Clinical Prospective Analysis of 451 Patients

Contact Info

Product

Resources

About